PL3679016T3 - Postacie stałe 2-(5-(4-(2-morfolinoetoksy)fenylo)pirydyn-2-ylo)-n-benzyloacetamidu - Google Patents

Postacie stałe 2-(5-(4-(2-morfolinoetoksy)fenylo)pirydyn-2-ylo)-n-benzyloacetamidu

Info

Publication number
PL3679016T3
PL3679016T3 PL18854688.1T PL18854688T PL3679016T3 PL 3679016 T3 PL3679016 T3 PL 3679016T3 PL 18854688 T PL18854688 T PL 18854688T PL 3679016 T3 PL3679016 T3 PL 3679016T3
Authority
PL
Poland
Prior art keywords
benzylacetamide
morpholinoethoxy
pyridin
phenyl
solid forms
Prior art date
Application number
PL18854688.1T
Other languages
English (en)
Polish (pl)
Inventor
Michael P. Smolinski
Original Assignee
Atnx Spv, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3679016(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv, Llc filed Critical Atnx Spv, Llc
Publication of PL3679016T3 publication Critical patent/PL3679016T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18854688.1T 2017-09-07 2018-09-07 Postacie stałe 2-(5-(4-(2-morfolinoetoksy)fenylo)pirydyn-2-ylo)-n-benzyloacetamidu PL3679016T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Publications (1)

Publication Number Publication Date
PL3679016T3 true PL3679016T3 (pl) 2026-03-02

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18854688.1T PL3679016T3 (pl) 2017-09-07 2018-09-07 Postacie stałe 2-(5-(4-(2-morfolinoetoksy)fenylo)pirydyn-2-ylo)-n-benzyloacetamidu

Country Status (24)

Country Link
US (4) US10669236B2 (enExample)
EP (2) EP4674486A3 (enExample)
JP (3) JP7843116B2 (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN111278808B (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
ES (1) ES3056703T3 (enExample)
FI (1) FI3679016T3 (enExample)
HR (1) HRP20260002T1 (enExample)
IL (2) IL326637A (enExample)
LT (1) LT3679016T (enExample)
MX (2) MX2020002622A (enExample)
PL (1) PL3679016T3 (enExample)
PT (1) PT3679016T (enExample)
RS (1) RS67706B1 (enExample)
SG (1) SG11202001868RA (enExample)
SI (1) SI3679016T1 (enExample)
SM (1) SMT202500467T1 (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)
ZA (1) ZA202106139B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE602006019822D1 (de) * 2005-09-13 2011-03-10 Sicor Inc Reines rocuroniumbromid
ES2500165T3 (es) * 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
KR20090064400A (ko) * 2006-09-28 2009-06-18 머크 앤드 캄파니 인코포레이티드 Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
SI3592355T1 (sl) 2017-03-10 2026-04-30 Atnx Spv, Llc KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Also Published As

Publication number Publication date
US20220098152A1 (en) 2022-03-31
BR112020004419A2 (pt) 2020-09-08
SMT202500467T1 (it) 2026-03-09
RU2020112539A3 (enExample) 2022-04-19
DK3679016T3 (da) 2025-12-15
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
AU2023201010A1 (en) 2023-03-23
AU2018330163A1 (en) 2020-03-26
HRP20260002T1 (hr) 2026-02-27
CN111278808A (zh) 2020-06-12
TW201920160A (zh) 2019-06-01
MX2023001805A (es) 2023-03-13
AU2018330163B2 (en) 2023-02-02
KR102691700B1 (ko) 2024-08-02
IL272992A (en) 2020-04-30
CA3074831A1 (en) 2019-03-14
AU2023201010B2 (en) 2024-10-03
CN111278808B (zh) 2024-04-26
CN118439992A (zh) 2024-08-06
KR20240119192A (ko) 2024-08-06
JP2025131661A (ja) 2025-09-09
JP7843116B2 (ja) 2026-04-09
MX2020002622A (es) 2020-10-01
EP4674486A3 (en) 2026-03-25
LT3679016T (lt) 2026-02-10
SG11202001868RA (en) 2020-03-30
EP4674486A2 (en) 2026-01-07
RS67706B1 (sr) 2026-02-27
FI3679016T3 (fi) 2025-12-12
SI3679016T1 (sl) 2026-04-30
EP3679016A1 (en) 2020-07-15
US20200255380A1 (en) 2020-08-13
US20250115555A1 (en) 2025-04-10
ZA202106139B (en) 2026-04-29
RU2020112539A (ru) 2021-10-08
PT3679016T (pt) 2025-12-05
JP2020533412A (ja) 2020-11-19
US20190071402A1 (en) 2019-03-07
TWI815820B (zh) 2023-09-21
US10669236B2 (en) 2020-06-02
IL326637A (en) 2026-04-01
ES3056703T3 (en) 2026-02-24
US11230527B2 (en) 2022-01-25
WO2019051147A1 (en) 2019-03-14
JP2023157909A (ja) 2023-10-26
EP3679016A4 (en) 2021-09-29
EP3679016B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
IL280572A (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
SG11202104206SA (en) New heterocyclic compounds
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
IL260908B (en) Substituted 2-(het)aryl-imidazolyl-carboxyamides as pest control agents
IL256237B (en) Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid
EP3376865A4 (en) 4 - ((6- (2,4-difluorophenyl) -1,1-difluoro-2-HYDROXY-3- (1 H
PL3658547T3 (pl) Sposób wytwarzania n-(5-(4-(4-formylo-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-yloamino)-4-metoksy-2-morfolinofenylo)akrylamidu
IL257422A (en) (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
SI3544976T1 (sl) Hemihidrat proste baze N-(5-(aminosulfonil)-4-metil-1,3-tiazol-2-il)-N-metil-2-(4-(2-(piridi nil)-fenil)-acetamida
SG10202007913WA (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
DK3559010T3 (da) Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf
CA3307653A1 (en) An ethanesulfonate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
DK3853219T3 (da) Herbicidt virksomme substituerede phenylpyrimidinhydrazider
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
PT3247699T (pt) Processo para a produção de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo
GB201806488D0 (en) Heterocyclic TADF compounds
GB201808580D0 (en) Heterocyclic compounds
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
UA97377U (en) 3 - ((2-chloroethyl) thio) -5- (3,4,5-trimethoxyphenyl) -1h-1,2,4-triazole which exhibits hypoglycemic activity